ASVRX | NDVAX | ASVRX / NDVAX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 15 years | 14 years | - |
Gain YTD | 0.296 | 0.111 | 266% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 1000 | 250% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 5.28B | 3.32B | 159% |
Annual Yield % from dividends | 0.47 | 0.92 | 51% |
Returns for 1 year | 4.45 | 7.49 | 59% |
Returns for 3 years | -6.04 | -11.04 | 55% |
Returns for 5 years | 32.99 | 13.01 | 254% |
Returns for 10 years | 21.72 | 53.71 | 40% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
RINCX | 18.28 | 0.42 | +2.35% |
Victory RS Science and Technology C | |||
NRFYX | 10.86 | 0.13 | +1.21% |
Natixis AEW Global Focused Real Estate Y | |||
LAVRX | 14.79 | 0.13 | +0.89% |
Lord Abbett Fundamental Equity R3 | |||
FEQIX | 74.30 | 0.61 | +0.83% |
Fidelity Equity-Income | |||
TIQIX | 25.92 | 0.19 | +0.74% |
Touchstone Non-US ESG Equity Y |